Biodesix
Mixed Month for Diagnostics Stocks as 360Dx Top 30 Ticks up 1 Percent in November
Out of the 30 companies tracked by 360Dx, 13 saw their share prices increase, while 17 saw their stock prices decline.
Biodesix Q3 Revenues up 35 Percent
The company attributed its growth to increased adoption of its lung cancer risk assessment tests, while it highlighted recent and ongoing research supporting those products.
Biodesix Reports 50 Percent Q2 Revenue Jump, Raises Full-Year Guidance
The company reported a 43 percent increase in diagnostic testing revenue, driven primarily by the continued adoption of its Nodify Lung nodule risk assessment tests.
TD Cowen Initiates Coverage of Biodesix With Buy Rating
Analyst Dan Brennan wrote that lung nodule diagnostics is about a $4 billion market that is only about 1 percent penetrated, with Biodesix the only commercial player.
Biodesix Q1 Revenues Rise 63 Percent on Strong Lung Cancer Testing Figures
Lung cancer testing revenues grew 58 percent year over year, while biopharmaceutical services and other revenues more than doubled from a year ago.